Latest News About Samsung Bioepis

Here is the latest publicly available information on Samsung Bioepis, based on recent press releases and industry coverage:

Key developments

• SB3 trastuzumab biosimilar: The U.S. FDA accepted for review the Biologics License Application for SB3, a trastuzumab biosimilar. If approved, it would be marketed in the U.S. by Merck (MSD outside the U.S. and Canada) [Source: Business Wire via Ritzau, 2026-02-25].[2]
• SB5 adalimumab biosimilar candidate: FDA accepted for review the BLA for SB5, Samsung Bioepis’ adalimumab biosimilar, marking progress in a major immunology biosimilar program [Source: Business Wire via Ritzau, 2025-04-01].[1]
• Corporate restructuring context: In mid-2025 there were reports that Samsung Biologics planned to spin off Samsung Bioepis as part of a broader corporate restructuring, creating a holding entity (Samsung Epis Holdings) to oversee biosimilars and related development, with Samsung Bioepis to become a wholly owned unit of the new holding. This would separate CDMO operations from biosimilar and novel drug development activities [Source: Samsung Biologics spin-off reports, 2025-06-09].[3]
• Regulatory and pipeline activity in 2024–2024: Samsung Bioepis has a broad pipeline across immunology, oncology, ophthalmology, and other areas, with multiple regulatory and clinical activities reported in 2024, including Phase 3 program updates and abstracts for immunology assets (e.g., through 2024 GlobeNewswire coverage).[4][5]

What these mean for patients and markets

• U.S. regulatory progress: The FDA accepting BLA reviews for SB3 and SB5 indicates continued momentum for Samsung Bioepis biosimilars in the U.S. market, potentially expanding competition and affordability for reference biologics like trastuzumab and adalimumab if approved.[1][2]
• Potential market structure changes: The spin-off/holding Company plan could affect how Samsung Bioepis operates in partnership with Samsung Biologics and influence its strategic focus, timing of product launches, and IP strategy.[3]
• Ongoing pipeline: Samsung Bioepis continues to pursue biosimilar and potential oncology/ophthalmology assets, with periodic updates on regulatory submissions and clinical programs across regions.[6][4]

If you’d like, I can pull the exact press releases or recent articles and summarize them with direct quotes, or I can create a concise timeline of regulatory milestones for Samsung Bioepis in 2024–2026. Would you prefer a formal timeline or a quick bullet summary tailored to regulatory, clinical, or market impact?

Citations

• Samsung Bioepis SB5 Adalimumab biosimilar BLA accepted for review by FDA[1]
• Samsung Bioepis SB3 Trastuzumab biosimilar BLA accepted for review by FDA[2]
• Samsung Biologics spin-off plan and Samsung Bioepis’ position within the new holding structure[3]
• 2024 regulatory and clinical program updates for Samsung Bioepis[5][4]